Dynavax Appoints Ryan Spencer as Chief Executive Officer and to Board of Directors
“Through a rigorous, comprehensive search process, Ryan emerged as the right business leader to guide
Mr. Spencer, who joined Dynavax in 2006, has held roles of increasing responsibility, building from a foundation in corporate finance to business strategy and investor relations, and culminating in his role as Senior Vice President, Commercial. Since May of 2019, Mr. Spencer has served as the Company’s interim co-President, a role he shared with Mr. Novack.
Mr. Novack joined Dynavax in 2013, and has led the company’s technical operations, supply chain, and quality teams through FDA approval, launch, and commercialization of HEPLISAV-B. Mr. Novack has more than 30 years of relevant industry experience, with more than 20 years of direct vaccine industry experience. Prior to Dynavax, Mr. Novack was at Novartis where he served in various roles, including Global Head of Technical Operations and Supply Chain for Diagnostics, and Global Head of Manufacturing Strategy for Vaccines.
“I am honored to take on this role at a transformational time for
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential for HEPLISAV-B to become the emerging standard of care in preventing hepatitis B infection in adults and the potential U.S market opportunity for HEPLISAV-B. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events may differ materially from those anticipated in such forward-looking statements due to various risks and uncertainties inherent in our business, including, without limitation, the risk that that prescribers and other key decision-makers at potential purchasing entities may not make the decision to switch to HEPLISAV-B; and the timing and quantity of actual purchases; risks related to market adoption and competing therapies; and risks related to whether payors will cover and provide timely and adequate reimbursement for HEPLISAV-B. These and other risks are described in the "Risk Factors" section of our Quarterly Report on Form 10-Q for the quarter ended
Investor Relations Advisory Solutions
Source: Dynavax Technologies Corporation